PsychiatricTimes Members: Login | Register

|     

PsychiatricTimes SearchMedica Medline Drugs

Powered by SearchMedica

 
Risk Assessment
News
Current Issues
Blogs
Special Reports
CME
Conferences
Resources
Careers
Multimedia
About Us
 

Home » Attention-Deficit/Hyperactivity Disorder

Psychiatric Times. Vol. 24 No. 4
Pages: 1  2  3  
Previous Next
 

Treating Adults With Attention-Deficit/Hyperactivity Disorder

By Robert Horst, MD | April 1, 2007
Dr Horst is assistant clinical professor of psychiatry at the University of California, Davis and medical director for Sacramento County Child and Adolescent Psychiatric Services. He reports no conflicts of interest regarding the subject of this article

Pharmacotherapy of ADHD
Just as with children, stimulants and atomoxetine(Drug information on atomoxetine) are the mainstay treatment for adults with ADHD. FDA-approved medications for ADHD treatment in adults include mixed amphetamine salts, dexmethylphenidate, and atomoxetine. Please see the Table for a summary of specific FDA-approved medications for adults with ADHD. Package inserts should be reviewed for complete prescribing details. All other medications discussed here are off-label. The mechanism of action for medications used to treat ADHD is thought to involve the neurotransmission of dopamine and/or norepinephrine(Drug information on norepinephrine). Nicotinic agonists may hold some promise and histaminergic systems have been hypothesized to be involved in the pathophysiology of ADHD.

                   
  TABLE
Summary of FDA-approved medications for
adults with attention-deficit/hyperactivity disorder
  Medication   Starting dosage   Maximum dosage   Common adverse effects    
 
  Amphetamine salts-XR   20 mg/d   60 mg/d   Dry mouth, loss of appetite, insomnia,
weight loss, headache, nausea, anxiety, agitation,
dizziness, tachycardia, diarrhea
   
 
  Dexmethylphenidate-XR   10 mg/d   20 mg/d   Headache, dry mouth, anxiety, dyspepsia,
pharyngolaryngeal pain, feeling jittery, dizziness
   
 
  Atomoxetine   40 mg/d (increase to 80 mg/d after 3 days)   100 mg/d   Constipation, dry mouth, nausea, decreased appetite, dizziness, insomnia, decreased libido, ejaculatory problems, impotence, urinary problems, dysmenorrhea    
 
 
 
XR, extended release.
Source: FDA Web site.

Stimulants
Amphetamine salts and methylphenidate(Drug information on methylphenidate) preparations have established efficacy in adults with ADHD.2,13,14 The mechanism of action for stimulants is thought to be primarily mediated through dopamine(Drug information on dopamine)rgic neurotransmission.15 Effective dosages in adults should be based on weight and may be significantly higher than the dosages known to be effective in children. For example, a recent study on the use of osmotic-release oral system methylphenidate in adults suggested an optimal dosage of 1.3 mg/kg/d.13 Adults in this study had a higher incidence of anorexia, dry mouth, moodiness, anxiety, insomnia, cardiovascular complaints, and dizziness.13

Cardiovascular complaints may be of concern in adults more so than in children. Because of the higher incidence of cardiovascular disease, including hypertension, routine monitoring is strongly recommended.2,13 In addition, the high rate of comorbidity in adults with ADHD is a factor, because stimulants can worsen psychosis, mood, and anxiety. The use of stimulant medication in adults with comorbid substance use disorders is particularly problematic given the potential for abuse. However, long-acting formulations are a reasonable option with less potential for abuse.13

Atomoxetine
Multiple studies have confirmed the efficacy of atomoxetine in treating adults with ADHD. Atomoxetine is primarily a norepinephrine reuptake inhibitor, although it may secondarily affect dopamine levels.15 It may be particularly useful in adults with ADHD, because it can alleviate anxiety symptoms and has no abuse potential.15 Atomoxetine may be considered first in adults with comorbid substance use disorders, anxiety disorders, or mood disorders.16 It is generally well tolerated; common adverse effects observed in adults include insomnia and GI and genitourinary symptoms.15 Increases in blood pressure and pulse have been observed in adults; therefore, atomoxetine should be used with caution in the context of cardiovascular risk factors such as hypertension.15

Antidepressants
Numerous antidepressant medications have been used to treat ADHD. However, there is limited data supporting their use and published trials typically involved small numbers and high dropout rates.17

Perhaps the strongest evidence supports the use of desipramine, which has been found to have similar efficacy to stimulants.17 The results of a 6-week, double-blind, placebo-controlled trial showed desipramine to be effective in the treatment of adult ADHD; however, adverse effects and potential for overdose lethality limit its usefulness.18

Bupropion is frequently used to treat ADHD. A few small studies support its use in adults. Bupropion's mechanism of action is unclear but may be related to indirect agonism of norepinephrine and dopamine.19

A double-blind, placebo-controlled, randomized trial of 40 adults with ADHD20 and a recent, larger study involving 162 adults over an 8-week treatment period21 supported its use. The latter study used once-daily dosing of bupropion extended-release (XL) and demonstrated effect sizes similar to those seen with atomoxetine for the treatment of adult ADHD.21 The study excluded adults with comorbid mood or anxiety disorders, suggesting that the benefit attained with bupropion was independent of any antidepressant or anxiolytic effect, and bupropion-XL was generally well tolerated with no serious adverse events.21 The demonstrated efficacy of bupropion in the treatment of depression suggests that it may be used as monotherapy in patients with comorbid ADHD and depression.

In a preliminary study, venlafaxine was shown to effectively treat ADHD in adults with comorbid ADHD and depression.22 Venlafaxine alone was found to be comparable in efficacy to a combination of stimulants and antidepressants, suggesting that venlafaxine may also be an option as monotherapy for patients with comorbid depression and ADHD.22 There are no controlled studies using venlafaxine for the treatment of ADHD and more research is needed.

Monoamine oxidase inhibitors and other tricyclic antidepressants besides desipramine have been used to treat ADHD with varying levels of success, but their use is limited by problematic adverse effects. There is little evidence supporting the use of SSRIs, possibly because of their lack of activity on norepinephrine and dopamine systems.2

α-Adrenergic agonists
The central α-agonists clonidine(Drug information on clonidine) and guanfacine(Drug information on guanfacine) are often used in the treatment of ADHD, but there is little data to support their use, particularly in adults. Potential adverse effects include rebound hypertension, dizziness, and transient sedation.2,23 Cardiovascular monitoring is recommended.

Pages: 1  2  3  
Previous Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.





  • Dulcan M. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry. 1997;36(suppl 10):85S-121S.


 
TOPIC INDEX

Addiction Medicine
Alzheimer Disease
Anxiety Disorders
ADHD
Bipolar Disorder
Child & Adolescent Psychiatry
Dementia
Depression
DSM-5
Geriatric Psychiatry

 

Health Care Reform
Major Depressive
Disorder
OCD
Personality Disorders
Schizoaffective Disorder
Schizophrenia
Sleep Disorders
Somatoform Disorders
All Topics

 


 
RELATED TOPICS

Attention deficit and disruptive behavior disorders
Hyperkinetic syndrome
Minimal brain dysfunction

 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Developmental Psychopathology Comes of Age
  • Grief and Depression: The Sages Knew the Difference
  • The Moral Struggles of Practicing Psychiatrists
  • Update on Mental Health Benefits and Substance Use Disorder Services Under the Affordable Care Act
  • Psychiatry and the Myth of “Medicalization”
  • Grief and Depression: The Sages Knew the Difference
  • Developmental Psychopathology Comes of Age
  • Psychiatry and the Myth of “Medicalization”
  • Synthetic Cathinones: Signs, Symptoms, and Treatment
  • Journey of the Traumatized Hero: Kerouac’s On the Road and Gandhi’s Railroad Ride
  • Eco-Psychiatry: Why We Need to Keep the Environment in Mind
  • DSM-5: Where Do We Go From Here?
  • Suicidal Behavior: A Separate Diagnosis
  • New Insight Into the Neurobiology of Depression
  • Cultural Psychiatry and the 'No-Chicken' Doctor
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • Psychiatry and the Myth of “Medicalization”
  • Grief and Depression: The Sages Knew the Difference
  • Is it Time for a Treatment Manual to Complement DSM-5?
  • Diagnosis and its Discontents: The DSM Debate Continues
  • Lamotrigine for Major Depressive Disorder Is Inappropriate
  • Psychiatry and the Myth of “Medicalization”
  • Parity Laws: Powerful Weapon—or Pipe Dream?
  • The Moral Struggles of Practicing Psychiatrists
  • DSM-5 Won’t Solve the Overdiagnosis Problem—But Clinicians Can
  • NIMH vs DSM 5: No One Wins, Patients Lose
Click here to subscribe to our newsletter
 
CAREER CENTER

  •   Featured Jobs  
  •    Resources   
  • Psychiatry and Nurse Practitioner Opportunities
  • Associate Medical Director - Psychiatrist Delray Beach, Florida
  • Retiring Child Psychiatrist Seeks Replacement August 2010 or Before
  • Chairperson, Dept of Psychiatry Needed
  • FT Staff Psychiatrist - Excellent Benefits
  • BC Adult and Child Psychiatrits - PT and FT Positions Available
  • Managing Risks When Practicing in Three-Party Care Settings
  • 12 Tips for Making Your Practice Greener
  • Keys to Avoiding Malpractice: Standard of Care in Psychiatric Practice
  • Take This Job and Shove It
  • Merging Administrative and Academic Careers in Psychiatry


 
SearchMedica Search Result

Find peer-reviewed literature and websites for practicing medical professionals

CME on Adhd
Evidence on Adhd
Guidelines on Adhd
Patient Education on Adhd
Clinical Trials on Adhd
Practical Articles on Adhd
Research and Reviews on Adhd
All "Adhd" results

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy